CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
CC-10004drug
Likely dose
CC-10004 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00708916
NCT00708916Phase 2Completed
CompareCT.gov

Clinical and Immune-modulating Effects of CC-10004 in Discoid Lupus Erythematosus

NYU Langone Health·interventional·Posted Jul 3, 2008·Updated Mar 3, 2021

In Brief

A Phase 2 clinical trial evaluating CC-10004 for Discoid Lupus Erythematosus. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiscoid Lupus Erythematosus
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 3, 2008
Enrollment StartJun 1, 2008
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.0 years ago

Interventions

CC-10004drug

20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment